Dianthus Therapeutics, Inc. (DNTH): Total Liabilities
$37.52M
As of 2025-12-31
$41.25M
As of 2026-06-30
+58.3%
3-year compound annual growth
+16.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.52M | +74.3% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $21.53M | +104.4% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $10.54M | +11.4% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $9.45M | -45.2% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $17.26M | -2.5% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $17.71M | -12.8% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $20.32M | +74.2% | 2021-03-03, Balance as of period end |
| 2018-12-31 | $11.66M | +181.6% | 2020-03-03, Balance as of period end |
| 2017-12-31 | $4.14M | n/a | 2019-03-19, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $2.53M | +67.1% |
| Bio Essence Corp (BIOE) | 2025-12-31 | $2.50M | -23.2% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $2.52M | -19.0% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $17.11M | -48.4% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $422.65M | -4.3% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $14.00M | +18.0% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.10M | +34.7% |
Compare DNTH, LPCN, BIOE, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗